ILK-IN-3

ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model[1][2].

Product Specifications

CAS Number

[6975-75-3]

Product Name Alternative

E64d; E64c ethyl ester

UNSPSC

12352005

Hazard Statement

H317, H319

Target

Ser/Thr Kinase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ilk-in-3.html

Purity

99.62

Solubility

DMSO : 83.33 mg/mL (ultrasonic)

Smiles

NC1=NNC(N)=C1/N=N/C2=CC=C(OC)C=C2

Molecular Formula

C10H12N6O

Molecular Weight

232.24

Precautions

H317, H319

References & Citations

[1]Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11 (9) :826-38.|[2]Mavrogeni ME, et al. A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1α inhibitor. Future Med Chem. 2018 Oct;10 (20) :2411-2430.